A. Menarini Pharma GmbH ist eine österreichische Tochtergesellschaft der Menarini Group/Florenz.
Lesen Sie die neuesten Nachrichten von der Menarini Gruppe.
A. Menarini Pharma GmbH is an Austrian subsidiary of the Menarini Group/Florence.
Read the latest news from the Menarini Group.
Priligy® is a medication indicated for the treatment of premature ejaculation (EP) in adult men between 18 and 64 years of age. Priligy® is indicated for the treatment of premature ejaculation (ejaculatio praecox, EP) in adult men between the ages of 18 and 64.1
Priligy® (dapoxetine) is the first and currently the only approved oral medication for the most common male sexual dysfunction, premature ejaculation (ejaculatio praecox).2 Due to its rapid onset of action, Priligy® can be taken 1-3 hours before sexual intercourse, if needed. Priligy® significantly prolongs intravaginal latency to ejaculation (IELT)3,4 and results in significantly improved control over ejaculation.4 Efficacy and good tolerability have been demonstrated in studies involving over 6,000 men.4
Priligy® should only be prescribed to patients who meet the following criteria:1
• An intravaginal latency to ejaculation (IELT) of less than two minutes; and
• persistent or recurrent ejaculation with minimal sexual stimulation before, during, or shortly after penetration and sooner than the patient desires; and
• marked personal distress or interpersonal problems as a result of EP, and
• inadequate control over ejaculation and
• a history of premature ejaculation during most attempts at a sexual act during the previous 6 months
Priligy® should be used only as needed 1 to 3 hours before anticipated sexual activity. Priligy® should not be prescribed to men to delay ejaculation without prior diagnosis of EP.
Priligy® is not intended for regular daily use. Priligy® should be taken only before planned sexual activity. Priligy® should not be taken more frequently than once every 24 hours. If individual response is inadequate at a dose of 30 mg and the patient has not experienced moderate or severe adverse reactions or prodromal symptoms suggestive of syncope, the dose may be increased to a maximum recommended dose of 60 mg. No increase in dose to 60 mg should be made if the patient has demonstrated an orthostatic response to the initial dose.1
References: 1 Drug information Priligy® 2 Salonia A. et al, EAU Guidelines on Sexual and Reproductive Health 2021; 3 McCarty EJ et al, Core Evidence 2012; 7: 1-14, 4 McMahon CG et al, J Sex Med 2011; 8: 524-539
AT-WEB-25-10-2021